Floatz logo

Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide

Glioblastoma

Oblato, Inc.Small moleculePhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
65/ 100

Competitive context

341 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB
Camustine
Leland Metheny
Phase 3BB
(+)-Vincristine
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide is also rated in:

malignant gliomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
brain glioblastomaDormant
B
Indicative · Phase 2
57 / 100
View asset →
astrocytic tumorActive
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →